Dingdang Health Technology Group Ltd. disclosed that its issued share capital remained unchanged at 1.25 billion ordinary shares as of 3 June 2026, with no treasury shares on hand.
From 19 May to 3 June 2026 the company repurchased a total of 6.68 million shares—equivalent to approximately 0.53% of its existing share base—at volume-weighted average prices ranging between HK$0.83 and HK$0.96 per share. Aggregate consideration for these purchases is calculated at roughly HK$6.03 million, based on the prices and volumes reported.
The latest tranche, executed on 3 June 2026, involved 561,500 shares bought back on the Hong Kong Stock Exchange at prices between HK$0.81 and HK$0.87 per share, for a total outlay of HK$0.48 million. All shares repurchased during the period remain outstanding pending formal cancellation.
Under the shareholder mandate granted on 28 May 2025, Dingdang Health may repurchase up to 131.95 million shares. Including the most recent purchases, 71.50 million shares have been bought back to date under this authority, representing 5.42% of the company’s issued shares at the time the mandate was approved.
In accordance with Hong Kong listing rules, the company is subject to a 30-day moratorium on new share issuances or treasury share disposals, effective until 3 July 2026.
Comments